Rockefeller Capital Management
FULC icon

Rockefeller Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Rockefeller Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94K Sell
529
-590
-53% -$3.59K ﹤0.01% 4438
2026
Q1 		$8.58K Buy
1,119
+895
+400% +$8.3K ﹤0.01% 4064
2025
Q4 		$2.53K Buy
+224
New +$2.28K ﹤0.01% 4262

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rockefeller Capital Management's FULC Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 53% in Q2 2026, selling an estimated $3.59K and leaving 529 shares worth $1.94K. The position accounts for ﹤0.01% of the portfolio, ranked #4438.

Rockefeller Capital Management first reported a position in FULC in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.58K in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Rockefeller Capital Management held 529 shares of Fulcrum Therapeutics worth $1.94K as of Q2 2026.
  • Rockefeller Capital Management sold 590 Fulcrum Therapeutics shares in Q2 2026, an estimated $3.59K.
  • Fulcrum Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4438 holding.
  • Rockefeller Capital Management first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Fulcrum Therapeutics position peaked at $8.58K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.